- Home
- GDTC vs RADX Comparison
GDTC vs RADX Comparison
Compare GDTC & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- RADX
- Stock Information
- Founded
- GDTC 2018
- RADX 2021
- Country
- GDTC Singapore
- RADX Australia
- Employees
- GDTC N/A
- RADX N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- RADX
- Sector
- GDTC Health Care
- RADX
- Exchange
- GDTC Nasdaq
- RADX NYSE
- Market Cap
- GDTC 21.5M
- RADX 32.5M
- IPO Year
- GDTC 2023
- RADX N/A
- Fundamental
- Price
- GDTC $1.89
- RADX $4.64
- Analyst Decision
- GDTC Buy
- RADX Strong Buy
- Analyst Count
- GDTC 1
- RADX 3
- Target Price
- GDTC $5.00
- RADX $15.00
- AVG Volume (30 Days)
- GDTC 18.1K
- RADX 17.9K
- Earning Date
- GDTC 01-01-0001
- RADX 02-26-2025
- Dividend Yield
- GDTC N/A
- RADX N/A
- EPS Growth
- GDTC N/A
- RADX N/A
- EPS
- GDTC N/A
- RADX N/A
- Revenue
- GDTC $368,838.00
- RADX $204,609.00
- Revenue This Year
- GDTC $5.37
- RADX N/A
- Revenue Next Year
- GDTC N/A
- RADX N/A
- P/E Ratio
- GDTC N/A
- RADX N/A
- Revenue Growth
- GDTC N/A
- RADX N/A
- 52 Week Low
- GDTC $1.20
- RADX $3.50
- 52 Week High
- GDTC $4.05
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- GDTC 37.08
- RADX N/A
- Support Level
- GDTC $1.85
- RADX N/A
- Resistance Level
- GDTC $1.95
- RADX N/A
- Average True Range (ATR)
- GDTC 0.10
- RADX 0.00
- MACD
- GDTC -0.02
- RADX 0.00
- Stochastic Oscillator
- GDTC 28.00
- RADX 0.00
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.